Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 232

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 232
---
 financial performance criteria and was paid to him (according to the definition contained in the NASDAQ listing rules) based on financial information that has been determined to be erroneous and has required accounting restatement to correct an error in previously-published financial statements. The policy applies to compensation paid on or after October 2, 2023. The clawback policy also applies to members of our Executive Committee and to our Head of Consolidation (equivalent to the Chief Accounting Officer within the meaning of the NASDAQ listing rules). Summary of changes made to the compensation policy for the Chief Executive Officer The table below summarizes adjustments made to the compensation policy for the Chief Executive Officer and to the content o f the information published in the compensation report, some of which have been discussed in depth with our shareholders.

| 2025                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          2024 |
| •Annual fixed compensation:–Annual fixed compensation is increased from €1,400,000 gross to€1,600,000 from 2025.•Equity-based compensation:–Given the increase in the number of performance shares it isproposed to award to the Chief Executive Officer in respect of 2025,it is proposed to increase the weighting of the TSR criterion from20% to 30%. To enable the TSR weighting to increase to 30%, theBusiness EPS weighting would reduce from 35% to 30%, and the FCFweighting from 25% to 20%; the R&D and CSR criteria would remainunchanged.Furthermore, in order to align with market practices, theBoard of Directors has decided to review the mechanism andremunerate Sanofi's relative positioning vis-à-vis the peer panel.•Transparency on performance criteria applicable to annual variablecompensation:–Transparency on the financial performance criteria applicable toannual variable compensation has been enhanced:information aboutthe thresholds (floor, target and maximum attainment level) used bythe Board of Directors to determine the overall attainment level andpayout is now published for each criterion. | •Annual variable compensation:–To reflect shareholder expectations, the weighting of financialobjectives was increased from 50% to 60% (removal of criteriarelated to business net income, business operating income marginand new asset growth, addition of a criterion based on business EPS.•Equity-based compensation:–The criterion related to business net income has been replaced bybusiness EPS.–To demonstrate Sanofi's commitment to delivering on the strategicroadmap, a criterion